Globus Medical

GMED

Market cap $12.9B

AUDUBON, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2026 after the market close on Thursday, May 7, 2026. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.

Robotics stocks like GMED, ADSK, MCHP and ROK gain momentum as physical AI, automation and medical robotics drive a major industry growth wave in 2026.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GMED rides on NuVasive synergies, strong cash flow and rapid innovation, but macro pressures and rising costs cloud its near-term outlook.

Globus Medical (GMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BE, SM, KRUS, GMED and BP have been added to the Zacks Rank #1 (Strong Buy) List on April 8th, 2026.

Flowserve, California Resources and Globus Medical stand out as sales-growth buys as oil spikes and Iran-Strait tensions shake markets.

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock?

AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the company of his decision to step down from the Board of Directors effective immediately and will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026.

GMED, TCMD and IRMD tap GenAI to boost diagnostics and workflows, but high costs, regulation gaps and macro pressures still weigh on MedTech growth.